Current:Home > ContactFDA approves first postpartum depression pill -PrimeWealth Guides
FDA approves first postpartum depression pill
View
Date:2025-04-12 17:55:25
WASHINGTON (AP) — Federal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
The Food and Drug Administration on Friday granted approval of the drug, Zurzuvae, for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.
“Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings,” said Dr. Tiffany Farchione, FDA’s director of psychiatric drugs, in a statement.
Postpartum depression affects an estimated 400,000 people a year, and while it often ends on its own within a couple weeks, it can continue for months or even years. Standard treatment includes counseling or antidepressants, which can take weeks to work and don’t help everyone.
The new pill is from Sage Therapeutics, which has a similar infused drug that’s given intravenously over three days in a medical facility. The FDA approved that drug in 2019, though it isn’t widely used because of its $34,000 price tag and the logistics of administering it.
The FDA’s pill approval is based on two company studies that showed women who took Zurzuvae had fewer signs of depression over a four- to six-week period when compared with those who received a dummy pill. The benefits, measured using a psychiatric test, appeared within three days for many patients.
Sahar McMahon, 39, had never experienced depression until after the birth of her second daughter in late 2021. She agreed to enroll in a study of the drug, known chemically as zuranolone, after realizing she no longer wanted to spend time with her children.
“I planned my pregnancies, I knew I wanted those kids but I didn’t want to interact with them,” said McMahon, who lives in New York City. She says her mood and outlook started improving within days of taking the first pills.
“It was a quick transition for me just waking up and starting to feel like myself again,” she said.
Dr. Kimberly Yonkers of Yale University said the Zurzuvae effect is “strong” and the drug likely will be prescribed for women who haven’t responded to antidepressants. She wasn’t involved in testing the drug.
Still, she said, the FDA should have required Sage to submit more follow-up data on how women fared after additional months.
“The problem is we don’t know what happens after 45 days,” said Yonkers, a psychiatrist who specializes in postpartum depression. “It could be that people are well or it could be that they relapse.”
Sage did not immediately announce how it would price the pill, and Yonkers said that’ll be a key factor in how widely its prescribed.
Side effects with the new drug are milder than the IV version, and include drowsiness and dizziness. The drug was co-developed with fellow Massachusetts pharmaceutical company Biogen.
Both the pill and IV forms mimic a derivative of progesterone, the naturally occurring female hormone needed to maintain a pregnancy. Levels of the hormone can plunge after childbirth.
Sage’s drugs are part of an emerging class of medications dubbed neurosteroids. These stimulate a different brain pathway than older antidepressants that target serotonin, the chemical linked to mood and emotions.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
veryGood! (14779)
Related
- Rolling Loud 2024: Lineup, how to stream the world's largest hip hop music festival
- Kate Gosselin Says Son Collin Has “Multiple Psychiatric Diagnoses” in Response to Estrangement Allegation
- After Litigation and Local Outcry, Energy Company Says It Will Not Move Forward with LNG Plant in Florida Panhandle
- The 16 Best Beauty Launches From July 2023: Rare Beauty, Rhode, Kylie Cosmetics, Olaplex, Tower 28 & More
- Who's hosting 'Saturday Night Live' tonight? Musical guest, how to watch Dec. 14 episode
- In Oregon Timber Country, a Town Buys the Surrounding Forests to Confront Climate-Driven Wildfires
- As Texas Cranks Up the AC, Congested Transmission Lines Cause Renewable Power to Go to Waste
- Joey King Shares Glimpse Inside Her Bachelorette Party—Featuring NSFW Dessert
- Pregnant Kylie Kelce Shares Hilarious Question Her Daughter Asked Jason Kelce Amid Rising Fame
- Sarah Michelle Gellar Shares Rare Photo of Her and Freddie Prinze Jr.'s 2 Kids on Italian Vacation
Ranking
- Israel lets Palestinians go back to northern Gaza for first time in over a year as cease
- Get $173 Worth of Peter Thomas Roth Top-Selling Skincare Products for Just $53
- Why Oscar De La Hoya Says He Let Travis Barker and Shanna Moakler Raise Daughter Atiana
- Why Lady Gaga Asked Joker Crew to Call Her This Fake Name on Set
- Megan Fox's ex Brian Austin Green tells Machine Gun Kelly to 'grow up'
- Vanderpump Rules’ Ariana Madix and Tom Sandoval Still Live Together 4 Months After Breakup
- University of Iowa Football Alum Cody Ince Dead at 23
- Married To Medicine Star Quad Webb's 3-Year-Old Great Niece Drowns In Her Pool
Recommendation
Can Bill Belichick turn North Carolina into a winner? At 72, he's chasing one last high
Shakira Is Facing Another Tax Fraud Investigation in Spain
Come on Barbie, Let’s Go Shopping: Your Guide to the Best Barbie Collabs: Barefoot Dreams, Crocs & More
Carlee Russell's disappearance was 'hoax'; charges possible, police say
See you latte: Starbucks plans to cut 30% of its menu
Seaside North Carolina town overrun with hundreds of non-native ducks
Disney Singer Lea Salonga Calls Out Fans for Sneaking Backstage to Take Pic
The 16 Best Beauty Launches From July 2023: Rare Beauty, Rhode, Kylie Cosmetics, Olaplex, Tower 28 & More